UCB de­parts in­dus­try trade group BIO, fol­low­ing Pfiz­er's ex­it late last year

Brus­sels-based bio­phar­ma com­pa­ny UCB con­firmed Thurs­day that it de­cid­ed not to re­new its mem­ber­ship in the in­dus­try group BIO in 2024, the sec­ond high-pro­file ex­it from the or­ga­ni­za­tion in re­cent months.

“We rou­tine­ly eval­u­ate our en­gage­ment across trade as­so­ci­a­tions and have de­cid­ed not to re­new our mem­ber­ship with the Biotech­nol­o­gy In­no­va­tion Or­ga­ni­za­tion (BIO) for 2024,” a UCB spokesper­son said via email. “We will re­main mem­bers of the Phar­ma­ceu­ti­cal Re­search and Man­u­fac­tur­ers As­so­ci­a­tion of Amer­i­ca (PhRMA) and the Na­tion­al Phar­ma­ceu­ti­cal Coun­cil (NPC), among oth­ers.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER